Clin2
NCT06510699Possibly a fitRecruiting

Genetics to improve fungal infection treatment

Fungal InfectionHaematological MalignancyBlood CancerInfectious Disease

Part of Blood & lymphatic, Cancer, Infections clinical trials.

This trial tests if using genetic information can help doctors choose the right dose of the antifungal drug voriconazole. It aims to improve treatment and reduce side effects for people with fungal infections.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
104 people
Ages
2 years and older
Study type
Interventional

Who can take part

  • You are 2 years old or older.
  • You have decided to take the medication voriconazole.
  • You are admitted to a hospital participating in the trial or can come for regular follow-up visits.
  • You have not received a stem cell transplant from a donor without having a DNA sample from before the transplant.
  • You are not expected to pass away within the next 7 days.
  • You have not been in this trial before.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06582186Not yet recruiting· Phase 4
Personalized voriconazole dosing for blood cancer patients

This study is testing a personalized way to decide the first maintenance dose of voriconazole, an antifungal medicine for people with blood cancers. It uses a genetic test to help determine the best dose for you.

Grenoble
NCT03828773Recruiting
Azole antifungal prevention for leukemia during low white blood counts

This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.

Ghent, Belgium
NCT07135778Recruiting
Combination antifungal therapy for fungal infections in blood cancer

This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.

Tianjin, Tianjin Municipality
NCT07559032Not yet recruiting
Amphotericin B for Fungal Infections in Blood Cancer Patients

This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.

Beijing, Beijing Municipality
NCT06678113Recruiting· Phase 1/Phase 2
Testing a new IV drug for serious fungal infections

This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.

Dehli, Haryana
NCT07763184Not yet recruiting
Detecting fungal infections in blood cancer patients

This study tests whether a sensitive blood test can find hidden fungal infections in people with blood cancers. It may help your doctor start the right treatment sooner.

Guangzhou, Guangdong

Hear when a new Fungal Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.